Free Trial
NASDAQ:CRBU

Caribou Biosciences (CRBU) Stock Price, News & Analysis

Caribou Biosciences logo
$1.95 -0.08 (-3.94%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.94 0.00 (-0.26%)
As of 08/1/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Caribou Biosciences Stock (NASDAQ:CRBU)

Key Stats

Today's Range
$1.86
$1.99
50-Day Range
$0.97
$2.48
52-Week Range
$0.66
$3.00
Volume
1.25 million shs
Average Volume
1.94 million shs
Market Capitalization
$181.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Caribou Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

CRBU MarketRank™: 

Caribou Biosciences scored higher than 49% of companies evaluated by MarketBeat, and ranked 538th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Caribou Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Caribou Biosciences has received no research coverage in the past 90 days.

  • Read more about Caribou Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Caribou Biosciences are expected to decrease in the coming year, from ($1.64) to ($1.78) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Caribou Biosciences is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Caribou Biosciences is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Caribou Biosciences has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Caribou Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    5.71% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently decreased by 25.36%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Caribou Biosciences does not currently pay a dividend.

  • Dividend Growth

    Caribou Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.71% of the float of Caribou Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Caribou Biosciences has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Caribou Biosciences has recently decreased by 25.36%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Caribou Biosciences this week, compared to 4 articles on an average week.
  • Search Interest

    10 people have searched for CRBU on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Caribou Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Caribou Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.28% of the stock of Caribou Biosciences is held by insiders.

  • Percentage Held by Institutions

    77.51% of the stock of Caribou Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Caribou Biosciences' insider trading history.
Receive CRBU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Caribou Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CRBU Stock News Headlines

Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
CRBU Caribou Biosciences, Inc. - Seeking Alpha
See More Headlines

CRBU Stock Analysis - Frequently Asked Questions

Caribou Biosciences' stock was trading at $1.59 at the beginning of 2025. Since then, CRBU shares have increased by 22.6% and is now trading at $1.95.

Caribou Biosciences, Inc. (NASDAQ:CRBU) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The business earned $2.35 million during the quarter, compared to analyst estimates of $1.48 million. Caribou Biosciences had a negative net margin of 1,490.84% and a negative trailing twelve-month return on equity of 55.70%.

Caribou Biosciences (CRBU) raised $202 million in an IPO on Friday, July 23rd 2021. The company issued 13,500,000 shares at $14.00-$16.00 per share.

Top institutional investors of Caribou Biosciences include Aberdeen Group plc (0.97%), Green Alpha Advisors LLC (0.46%), Envestnet Asset Management Inc. (0.34%) and Y Intercept Hong Kong Ltd (0.15%). Insiders that own company stock include Rachel E Haurwitz, Barbara G Mcclung, Steven Kanner, Ryan Fischesser, Syed Ali-Aamir Rizvi and Sriram Ryali.
View institutional ownership trends
.

Shares of CRBU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Caribou Biosciences investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

Last Earnings
5/08/2025
Today
8/01/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRBU
CIK
1619856
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$3.00
Potential Upside/Downside
+335.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$149.10 million
Net Margins
-1,490.84%
Pretax Margin
-1,490.94%
Return on Equity
-55.70%
Return on Assets
-45.35%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.63
Quick Ratio
7.63

Sales & Book Value

Annual Sales
$9.92 million
Price / Sales
18.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.79 per share
Price / Book
0.70

Miscellaneous

Outstanding Shares
93,005,000
Free Float
85,304,000
Market Cap
$181.36 million
Optionable
Optionable
Beta
2.48

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:CRBU) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners